Parkinson’s, oxidative stress and inflammation
In recent years, there has been considerable interest in the role of oxidative stress (or free-radical damage) and how the body responds to inflammation, in the brains of people with Parkinson’s. These ‘stressor’ factors create an environment which is not conducive to normal function and signs of oxidative damage have been shown to appear long before nerve cells (neurons) actually degenerate in Parkinson’s:
- Oxidative stress is essentially an imbalance between the production of highly chemically reactive substances in cells and the ability of the body to counteract or detoxify their harmful effects, resulting in cell damage or cell death.
- Inflammation is the body’s attempt at self-healing; the aim being to remove harmful substances, including damaged or degenerated cells, and begin the healing process. When something harmful affects a part of the body, the biological response to try to remove it results in the signs and symptoms of inflammation.
Strong evidence now exists to support abnormal mitochondrial activity and increased oxidative stress, in the cause, development and effects of Parkinson’s. Mitochondria are small structures inside cells that are responsible for energy production. A complex interplay occurs between mitochondria and other cellular processes that affect cell survival, as mitochondria are also the main cellular source of waste products. There is also a plausible link between oxidative damage and the formation of abnormal aggregates of protein that are characteristic of Parkinson’s; oxidative damage is believed to have a role in alpha-synuclein clumping and impairment of the proper breakdown of these proteins.
There is now a great deal of research going on to explore methods of reducing the inflammation response in an effort to restrict the potential damage inflicted, and this, in turn, has led to a number of clinical trials.
More information about oxidative stress and inflammation
Webinar – Inflammation in Parkinson’s Rheumatoid arthritis and Parkinson’s Cure Parkinson’s approves funding for new iron removing drugA Review of Our 2023 Preclinical Projects
In 2023, Cure Parkinson’s has funded five new preclinical projects. These preclinical projects address a wide range of ‘targets’ to understand which drugs and which targets should be further…
Sun Pharma shines on c-ABL
Sun Pharma have published data on their new drug vodobatinib which is a c-ABL inhibitor – c-ABL is over-active in the brains of people with Parkinson’s.
Biotech Inhibikase develops new drug for Parkinson’s
Researchers have published laboratory data demonstrating the neuroprotective effects of a new potential drug for Parkinson’s called IkT-148009.
Results of FAIRPARK-II deferiprone trial published
The results of the most recent study of deferiprone in people with Parkinson’s (the FAIRPARK-II study) have been published in the New England Journal of Medicine.
A sub-study of azathioprine in Parkinson’s
There is increasing evidence that inflammation and the immune system might have contributory roles in the development and progression of Parkinson’s.
Inhibikase makes a case for c-Abl
Research has suggested that in some cases of Parkinson’s a protein called c-Abl tyrosine kinase is abnormally over-active and this contributes to nerve cell inflammation and eventual cell death….
Nicotinamide riboside for Parkinson’s: pilot results published
Researchers in Norway have published the promising results of a pilot clinical study of nicotinamide riboside for people with Parkinson’s.
The PROSEEK trial of KO706
Sun Pharma Advanced Research Company (SPARC) is conducting a phase 2 clinical trial to evaluate the safety and effectiveness of its experimental c-Abl inhibitor KO706 in people with early…
Encouraging trial results from Anavex
Recent positive results from biotech company Anavex Life Sciences have shown that when treated with their experimental drug, blarcamesine, individuals with Parkinson’s dementia had significant improvements in both motor…
Iron and the brain
Recent studies exploring iron levels in the brains of people with Parkinson’s have shown important implications for its use as a biomarker, as well as a way of potentially…
Rheumatoid arthritis and Parkinson’s
Recently, researchers have asked whether there is an association between Parkinson’s and rheumatoid arthritis: Could people with rheumatoid arthritis be at higher risk of developing Parkinson’s?
Cure Parkinson’s approves funding for new iron removing drug
Cure Parkinson’s continues to champion iron chelation for Parkinson’s. Trustees have now awarded a grant to develop the next generation of iron reducing drugs.
The need for novel c-Abl inhibitors
A protein called Abelson Tyrosine Kinase – or c-Abl – is believed to be involved in the biological processes leading to loss of dopamine neurons in the brains of people with Parkinson’s. In…